Insulet starts pivotal EVOLVE study for fully closed-loop Omnipod M

Insulet has enrolled the first participant in EVOLVE, its pivotal U.S. study of an investigational fully closed-loop Omnipod M system for adults with type 2 diabetes who use insulin. The company said the randomized controlled trial will enroll up to 350 adults ages 18 to 75 across as many as 40 U.S. sites, after receiving FDA investigational device exemption approval in March 2026. Unlike current automated insulin delivery approaches that still require some user input, Insulet says its fully closed-loop system is designed to eliminate bolusing, mealtime announcements, and startup settings. The company is targeting a 510(k) submission in 2027 and a commercial launch in 2028. (investor.insulet.com)

Why it matters: For veterinary professionals watching diabetes technology more broadly, EVOLVE is another sign that device makers are pushing toward lower-burden insulin management in type 2 diabetes, especially in primary care settings where Insulet says about 70% of these patients are managed. That matters because simplification, training burden, workflow fit, and safety oversight often determine whether new chronic-disease tools gain traction in everyday practice. The study also builds on earlier Insulet data: the company’s EVOLUTION 2 feasibility results, presented at ATTD 2026, showed average time in range of 68%, a 24-point improvement over standard injection therapy, while Insulet’s earlier SECURE-T2D pivotal program helped support Omnipod 5’s FDA clearance for adults with type 2 diabetes. (investor.insulet.com)

What to watch: Watch for enrollment updates, fuller EVOLVE protocol details, and whether Insulet stays on track for a 2027 FDA filing as it advances the platform amid heightened device-safety scrutiny following its March 12, 2026, correction for certain Omnipod 5 pods in the U.S. (investor.insulet.com)